Results are expressed as percentages for categorical variables and as medians (interquartile ranges) for the continuous variables.
γ -Glutamyl transferase (GGT), an enzyme involved in the metabolism of glutathione, is a second-generation enzymatic liver function test available for several decades. Previous studies have investigated the association between GGT and cardiovascular disease (CVD) events or cardiac mortality, but conflicting results were reported. 1, 2 Recently, a meta-analysis provided evidence that a high level of GGT is significantly associated with increased risk of stroke independently of alcohol intake. 3 We, therefore, evaluated the association of the measurement of serum GGT concentrations at the time of hospital admission with 1-year all-cause or CVD mortality in patients with acute ischemic stroke. Moreover, as serum GGT values differ significantly by sex, 2 it may also be interesting to examine whether serum GGT predicts the risk of mortality among men or women participants with stroke.
Patients and Methods

Setting
This prospective, multicenter cohort study was conducted in 4 stroke centers in China from January 2010 through December 2014. A complete description of study method has been reported previously. 4 In brief, vital signs, relevant comorbidities, risk factors, and stroke severity on admission as assessed by the National Institutes of Health Stroke Scale were recorded. GGT activity was measured in serum under fasting. The threshold value in our laboratory is <60 U/L in men and <40 U/L in women. We followed the participants for a median of 1 year (range, 12-13 months). The primary outcome measure was all-cause mortality, and secondary end point was CVD death (more information is shown in the online-only Data Supplement).
Comparisons for categorical baseline measurements were performed by Fisher exact test or Mann-Whitney U test.
For a more detailed exploration of the GGT-mortality relationship, we used Cox proportional hazards models to estimate hazard ratios and 95% confidence interval (CI) of all-cause and CVD mortality for quintiles of GGT (with lowest quintile as reference) and log GGT. To identify cutoff values for GGT to predict mortality from all-cause or CVD, we performed receiver-operating characteristic analyses. Moreover, all analyses were also performed separately for men and women. Statistical significance was defined as P<0.05 (Materials in the online-only Data Supplement).
Results
We recorded 5912 patients with stroke ( Figure I in the onlineonly Data Supplement). The baseline characteristics were described in Table I in the online-only Data Supplement. Patients with higher levels of GGT were older and more frequently were obese, with diabetes mellitus, had a previous CVD event, with high alcohol consumption, higher initial stroke severity, and are physically active, with larger infarct volume, or with higher levels of C-reactive protein, fasting blood glucose, and uric acid. In the follow-up, the total mortality and mortality from CVD were 17.9% and 12.3%, respectively. Associations of GGT with established risk factors were presented in the Table II in the online-only Data Supplement.
In the study, all-cause death risk (hazard ratios) was increased by 3.58 (95% CI, 1.46-6.15) per log unit of GGT. In both men (Table) and women (Table III in the onlineonly Data Supplement), raised GGT was also significantly (P<0.001) associated with total mortality from all-cause and CVD. The adjusted hazard ratios increased from Q2 to Q5 (with Q1 as reference; Figure 1 ). Elevated GGT revealed hazard ratios of 3.03 (95% CI, 1.99-4.54) and 3.24 (95% CI, 2.14-4.92) for all-cause and CVD mortality. Similarly, results were obtained from men (3.06; 95% CI, 2.16-4.99; 3.33; 95% CI, 2.23-5.52) and women (2.99; 95% CI, 1.86-4.07; 3.12; 95% CI, 2.10-5.12). Sex does not change those trends. Table IV in the online-only Data Supplement shows the sensitivities and specificities for selected threshold values of GGT predicting mortality from all-cause or total CVD. The receiver-operating characteristic analyses suggested GGT cutoff values of 15.5 U/L for men and 10.5 U/L for women with corresponding sensitivities of 66% and 74%, respectively. With an area under the curve of 0.69 (95% CI, 0.66-0.73), GGT showed a significantly greater discriminatory ability to predict all-cause mortality as compared with others factors ( Figure 2 CHD indicates coronary heart disease; CHF, congestive heart failure; CI, confidence interval; CVD, cardiovascular disease; GGT, γ-glutamyl transferase; and HR, hazard ratio.
*HRs (95% CIs) from Cox proportional hazards model adjusted for age, body mass index, frequency of exercise, systolic blood pressure, conventional vascular risk factors, National Institutes of Health Stroke Scale, infarct volume, stroke pathogenesis, stroke syndrome, smoking, drinking, work status, therapies before admission and serum levels of high-sensitivity C-reactive protein, glucose, total cholesterol, triglyceride, high-density lipoprotein, and low-density lipoprotein.
†Quintile values for GGT in Table I in the online-only Data Supplement. ‡GGT was logarithmically transformed. §P value for trend.
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Discussion
Our results found the association of circulating GGT with all-cause or CVD mortality in stroke for men and women, whereas GGT was positively and log-linearly associated with all-cause or CVD mortality in analyses adjusted for several established and potential predictors. It is imperative to emphasize targeted lifestyle intervention and more frequent medical interventions for patients with stroke, especially for these patients with the concentration of GGT not in the normal range.
Consistent with our findings, a study found that serum GGT was predictive of mortality in individuals with coronary artery disease. 5 However, another study suggested that elevated GGT was independently associated with the risk of 3-year all-cause mortality but not cardiac mortality in patients with diabetes mellitus and coronary artery disease. 6 Furthermore, KazemiShirazi et al 7 suggested that GGT was associated with mortality in both men and women. In this study, we found that elevated GGT levels were associated with all-cause or CVD mortality both in men and women. The strengths of this study are the prospective, multicenter cohort study, blinded outcome assessment, and thorough follow-up interviews. As a limitation, our results need validation in an independent cohort of patients. In addition, this observational study cannot determine the causal relationship between GGT and mortality events. Third, we did not obtain repeated GGT measurements but used baseline values, which is a potential limitation because changes could occur over time. Last, few events in the reference category (lowest quintile) of GGT particularly for the subgroups were obtained. Because of the small number of events, this will limit the number of covariates that can be included in the model. Thus, residual confounding cannot be completely excluded.
In conclusion, this study demonstrates that GGT is a useful prognostic marker of all-cause and CVD mortality in patients with ischemic stroke, independent of established conventional risk factors.
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